SCHEMBL1634508

SCHEMBL1634508

Brc1cc(N2CCCC2)ccn1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHKA P35790 1/20 0.52
HRH4 Q9H3N8 7/20 0.51
TERT O14746 3/20 0.44
ELOVL1 Q9BW60 1/20 0.43
CHRNB2 P17787 2/20 0.42
CHRNA4 P43681 2/20 0.42
IP6K1 Q92551 2/20 0.40
MAP4K4 O95819 1/20 0.39
S100B P04271 2/20 0.39
MAPT P10636 2/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
PKM P14618 1/20 0.39
ALOX15 P16050 1/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
KMT2A Q03164 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30900615 1.00 CHKA (0.52) CHKAHRH4TERTELOVL1CHRNB2
SCHEMBL31341814 0.98 HRH4 (0.54) CHKAHRH4TERTELOVL1CHRNB2
SCHEMBL5314278 0.98 HRH4 (0.54) CHKAHRH4TERTELOVL1CHRNB2
SCHEMBL25247515 0.96 HRH4 (0.47) CHKAHRH4TERTELOVL1CHRNB2
SCHEMBL26987219 0.83 HRH4 (0.59) HRH4MAPTMEN1ALDH1A1GAA
SCHEMBL30900618 0.83 LMNA (0.46) MAPTMEN1ALDH1A1LMNAALOX15
SCHEMBL3304237 0.83 LMNA (0.46) MAPTMEN1ALDH1A1LMNAALOX15
SCHEMBL8513639 0.80 HRH3 (0.47) HRH4MEN1ALOX15KMT2A
SCHEMBL24322274 0.79 RAD52 (0.53) HRH4MAPTALDH1A1GAAHTT
SCHEMBL29132185 0.77 HRH4 (0.35) HRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3710428-B1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2026-03-25 EP disclosed
EP-4577536-A1 PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY Hotspot Therapeutics, Inc. (US) 2025-07-02 EP disclosed
US-20250099457-A1 HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS CORCEPT THERAPEUTICS, INC. (US) 2025-03-27 US disclosed
US-12226412-B2 Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators CORCEPT THERAPEUTICS, INC. (US) 2025-02-18 US disclosed
EP-4434584-A2 HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS Corcept Therapeutics Incorporated (US) 2024-09-25 EP disclosed
US-20240307382-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ABBVIE INC. 2024-09-19 US disclosed
EP-4119561-B1 HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS CORCEPT THERAPEUTICS INC (US) 2024-09-11 EP disclosed
US-20240150321-A1 PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS, INC. 2024-05-09 US disclosed
CN-112204009-B Modulators of integrated stress pathways 卡里科生命科学有限责任公司 2024-05-07 CN disclosed
CN-117683016-A Synthesis of chiral 3, 4-disubstituted aminopyridine catalyst and application thereof in Black rearrangement 河南师范大学 2024-03-12 CN disclosed
US-7932254-B2 Pyrrolopyrazine kinase inhibitors Roche Palo Alto (US) 2011-04-26 US disclosed
US-7932254-B2 Pyrrolopyrazine kinase inhibitors Roche Palo Alto (US) 2011-04-26 US disclosed
US-7932254-B2 Pyrrolopyrazine kinase inhibitors Roche Palo Alto (US) 2011-04-26 US disclosed
EP-2247595-A1 PYRROLOPYRAZINE KINASE INHIBITORS F. Hoffmann-La Roche AG (CH) 2010-11-10 EP disclosed
WO-2009106445-A1 PYRROLOPYRAZINE KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-09-03 WO disclosed
WO-2009106445-A1 PYRROLOPYRAZINE KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-09-03 WO disclosed
US-20090215724-A1 Pyrrolopyrazine kinase inhibitors ROCHE PALO ALTO LLC 2009-08-27 US disclosed
US-20090215724-A1 Pyrrolopyrazine kinase inhibitors ROCHE PALO ALTO LLC 2009-08-27 US disclosed
US-20090215724-A1 Pyrrolopyrazine kinase inhibitors ROCHE PALO ALTO LLC 2009-08-27 US disclosed
WO-2007057775-A1 SPIROPIPERIDINE DERIVATIVES PFIZER LIMITED (GB) 2007-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150321-A1 PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY MALT1, BCL6, BCL3 CHKA 3444/4885HRH4 3003/4885TERT 2548/4885
US-20250099457-A1 HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS NR3C1, GRIN3A, NR3C2 CHKA 3794/4885HRH4 1067/4885TERT 3070/4885
US-12226412-B2 Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators NR3C1, GRIN3A, NR3C2 CHKA 3794/4885HRH4 1067/4885TERT 3070/4885
US-20240307382-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ATF4, ATF1, DDIT3 CHKA 3453/4885HRH4 2783/4885TERT 3811/4885
US-20090215724-A1 Pyrrolopyrazine kinase inhibitors SYK, ZAP70, JAK1 CHKA 2974/4885HRH4 1325/4885TERT 3441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.